Favipiravir treatment in Thai children with COVID-19: effectiveness, safety, and modeling drug exposure
Asian Biomedicine · 01.04.2026 · 20 (2) · 96-113
DOI: 10.2478/abm-2026-0011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Biomedicine, online erschienen am 30.04.2026. Verfasst von Sujittra Chaisavaneeyakorn und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Despite widespread favipiravir (FPV) use for coronavirus disease 2019 (COVID-19) in Thailand, pediatric clinical evidence remains limited.
Objectives
This study evaluated FPV’s effectiveness and safety for treating COVID-19 in children and adolescents.
Methods
This multicenter, retrospective, observational cohort study included patients ≤18 years old testing COVID-19 positive between July 2021 and December 2022 across 11 hospitals in Thailand. Patients were divided into those with and without chest X-ray-confirmed pneumonia. Patients who received FPV were treated with 35 mg/kg twice daily on day 1 and 15 mg/kg twice daily on days 2–5. Pharmacokinetic (PK) modeling estimated plasma exposure in children using scaled Thai adult data.
Results
Of 2,999 patients, 68.2% had no pneumonia. FPV recipients (n = 1,886) were mostly
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
- Department of Pediatrics, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen 40002, Thailand.
- Epidemiology and Biostatistics Section, Faculty of Public Health, Khon Kaen University, Khon Kaen 40002, Thailand.
- Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Department of Pediatrics, Bhumibol Adulyadej Hospital, Bangkok 10220, Thailand.
- Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Zitieren
APA
Chaisavaneeyakorn, S., Apiwattanakul, N., Techasaensiri, C., Tantawarak, N., Thinkhamrop, B., Rungmaitree, S., Phongjitsiri, S., Sudjaritruk, T., Anugulruengkitt, S., Kosalaraksa, P., Nivesvivat, T., Khantee, P., Bunjoungmanee, P., Takkinsatian, P., Kanjanaphan, T., Samakoses, R., Cressey, T. R., Pertinez, H., Owen, A., & Chokephaibulkit, K. (2026). Favipiravir treatment in Thai children with COVID-19: effectiveness, safety, and modeling drug exposure. Asian Biomedicine, 20(2), 96-113. https://doi.org/10.2478/abm-2026-0011
Vancouver
Chaisavaneeyakorn S, Apiwattanakul N, Techasaensiri C, Tantawarak N, Thinkhamrop B, Rungmaitree S, et al. Favipiravir treatment in Thai children with COVID-19: effectiveness, safety, and modeling drug exposure. Asian Biomedicine. 2026;20(2):96-113. doi:10.2478/abm-2026-0011
BibTeX
@article{Chaisavaneeyakorn2026,
author = {Chaisavaneeyakorn, Sujittra and Apiwattanakul, Nopporn and Techasaensiri, Chonnamet and Tantawarak, Nattakarn and Thinkhamrop, Bandit and Rungmaitree, Supattra and Phongjitsiri, Siriporn and Sudjaritruk, Tavitiya and Anugulruengkitt, Suvaporn and Kosalaraksa, Pope and Nivesvivat, Thirapa and Khantee, Puttichart and Bunjoungmanee, Pornumpa and Takkinsatian, Panit and Kanjanaphan, Thiraporn and Samakoses, Rudiwilai and Cressey, Tim R and Pertinez, Henry and Owen, Andrew and Chokephaibulkit, Kulkanya},
title = {Favipiravir treatment in Thai children with COVID-19: effectiveness, safety, and modeling drug exposure},
journal = {Asian Biomedicine},
year = {2026},
volume = {20},
number = {2},
pages = {96--113},
doi = {10.2478/abm-2026-0011}
}
EUVIMED